-
-
QCOR beats expectations and drops 16.5%... rough day... seems somebody knows something I don't.Comment
-
I've seen this before. If the company keeps making money, the stock gets too cheap to ignore....remember the mantra:Originally posted by Hobophobic View Post
earnings earnings earnings=============================
I am HUGE! Bring me your finest meats and cheeses.
- $$$MR. MARKET$$$Comment
-
Oh yea....we are most definitely BACK!=============================
I am HUGE! Bring me your finest meats and cheeses.
- $$$MR. MARKET$$$Comment
-
Yep. Look at that VOLUME too!
(Jumped in on the dip at 38.20 and really enjoying the ride... )
-AdamComment
-
TJX has been losing a long held, steady lead as it feels the heat of QCOR coming up around the outside. Will the sound of clipity clop give TJX the rush it needs or has QCOR just unleashed overwhelming power... it's going to be nose to nose.... And Mr. Meat & Cheese will be rolling in hay either way."It's easy to make money in the stock market" "Just buy a stock that goes up, and then sell it" "If it doesn't go up, don't buy it!" - Mark TwainComment
-
you seeeeees!!??=============================
I am HUGE! Bring me your finest meats and cheeses.
- $$$MR. MARKET$$$Comment
-
shorts are at it again...my this has been a fun ride!=============================
I am HUGE! Bring me your finest meats and cheeses.
- $$$MR. MARKET$$$Comment
-
Qcor
Was hoping you were not still in it. Oops!Originally posted by mrmarket View Post
Questcor plummets after Aetna rejects Acthar for most conditions
Questcor's (QCOR) stock is plunging after health insurance giant Aetna (AET) decided that the company's Acthar gel is either unnecessary or experimental in most cases, according to a posting on Aetna’s website as highlighted earlier today by short-selling blog Citron Research. Aetna found that Acthar isn't necessary for diagnostic testing of adrenocortical function or for corticosteroid-responsive conditions, and therefore will cease being reimbursed for those two indications. The insurer determined that Acthar is medically necessary as a test for infantile spasms, but is "experimental and investigational" for all other conditions. In mid-morning trading, Questcor tumbled $24.25, or 48%, to $26.27. The stock began declining precipitously after Citron Research highlighted Aetna’s findings in a new report on its website.Comment
-
Ouch ! Talk about timing. I bought yesterday and didn't check back until 10:30 this morning. I'll put on my barrel and sneak out to the doghouse.
-----------billyComment
-
Ouch billy! They're calling it a day traders' dream. Talk about bouncing up and down like a yoyo.Originally posted by billyjoe View PostOuch ! Talk about timing. I bought yesterday and didn't check back until 10:30 this morning. I'll put on my barrel and sneak out to the doghouse.
-----------billyComment
-
a lot of trading based on misinformation.=============================
I am HUGE! Bring me your finest meats and cheeses.
- $$$MR. MARKET$$$Comment
-
AET confirming to Reuters that its dropping coverage on majority of Acthars indications - QCORComment
-
Edited a tasteless joke here.Originally posted by riverbabe View PostWas hoping you were not still in it. Oops!
Questcor plummets after Aetna rejects Acthar for most conditions
Questcor's (QCOR) stock is plunging after health insurance giant Aetna (AET) decided that the company's Acthar gel is either unnecessary or experimental in most cases, according to a posting on Aetna’s website as highlighted earlier today by short-selling blog Citron Research. Aetna found that Acthar isn't necessary for diagnostic testing of adrenocortical function or for corticosteroid-responsive conditions, and therefore will cease being reimbursed for those two indications. The insurer determined that Acthar is medically necessary as a test for infantile spasms, but is "experimental and investigational" for all other conditions. In mid-morning trading, Questcor tumbled $24.25, or 48%, to $26.27. The stock began declining precipitously after Citron Research highlighted Aetna’s findings in a new report on its website."It's easy to make money in the stock market" "Just buy a stock that goes up, and then sell it" "If it doesn't go up, don't buy it!" - Mark TwainComment
-
Please illuminate the "tasteless joke". This is genuine commiseration. What are you trying to say?Originally posted by joshcord View PostComment
I have 22 consecutive profitable trades of 15% or better. How is this possible? Every day there are hundreds of stocks setting new highs, no matter what happens in the overall market. Many of these stocks are still at very reasonable valuations. Afraid of buying stocks at their highs? Think of it this way: a new high is really a future floor for companies with solid financial underpinnings. Quantitative momentum modeling makes it easy to identify stocks that can continue this upward momentum trend. Why does this happen? It's really very simple..ask me about what investors and cows have in common. I am $$$ MR. MARKET $$$. I AM HUGE!!! Bring me your finest meats and cheeses. You can join in on the fun. Register for free and you'll be able to post messages on this forum and also receive emails when $$$ MR. MARKET $$$ makes his own trades. ($$$MR. MARKET$$$ is a proprietary investor and does not provide individual financial advice. The stocks mentioned on this forum do not represent individual buy or sell recommendations and should not be viewed as such. Individual investors should consider speaking with a professional investment adviser before making any investment decisions.)
- If this is your first visit, be sure to check out the FAQ by clicking the link above. You may have to register before you can post: click the register link above to proceed. To start viewing messages, select the forum that you want to visit from the selection below.
Tweet
Comment